Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates

BRANFORD, Conn., Feb. 27, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2025, and provided a business update. Pipeline Achievements and Upcoming Milestones ATR-12 - Advancing Phase 1b Clinical Trial in Netherton Syndrome ATR-04 – Addressing an Unmet Need for Cancer Patients in a Multi-billion Dollar Market ...